Results from the randomized, open-label phase III KEYNOTE-204 study, presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program, suggested that pembrolizumab (Keytruda) was superior to brentuximab vedotin (Adcetris) in patients with relapsed or refractory classic Hodgkin lymphoma (R/R cHL).
In an interview with CancerNetwork®, John Kuruvilla, MD, of the Princess Margaret Cancer Centre, discussed the implications of the phase III KEYNOTE-204 trial and what these findings represent for this patient population.
Transcription:
It’s been an interesting study to think about because the population is actually both broad and focused in a way, so the real standard in this setting for a long time had been brentuximab vedotin, and that was based on the pivotal trial that had enrolled patients that had had disease progression only following autologous stem…